Emerald Bioscience (OTCMKTS:EMBI) Shares Down 6.6% – Here’s Why

Emerald Bioscience Inc. (OTCMKTS:EMBI)’s share price was down 6.6% during mid-day trading on Monday . The stock traded as low as $0.6467 and last traded at $0.6603. Approximately 307,414 shares were traded during trading, a decline of 98% from the average daily volume of 14,236,620 shares. The stock had previously closed at $0.7070.

Emerald Bioscience Trading Down 6.6%

The stock has a market capitalization of $177.01 million, a PE ratio of -8.25 and a beta of 0.43. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.43.

Emerald Bioscience Company Profile

Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.